Investigation of the NVT ALLEGRA Plus THV System in Patients With Severe Aortic Stenosis or Failed Surgical Aortic Bioprosthesis

A trial with no phase registered on ClinicalTrials.gov. The registry status is suspended. It plans to enroll 177 participants.

Also called NCT05804903

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 177 participants (planned count) (from the registry)
Sponsor
NVT GmbH (from the registry)
Registry
  • NCT NCT05804903
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Finland, Germany, Poland, Spain, Switzerland (from the registry)
Registry status
  • Suspended (from the registry)

Technical summary

Registry record NCT05804903. Allocation not applicable; no masking; primary purpose treatment. Start 2023-11-24 (actual); primary completion 2025-08-31 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Investigation of the NVT ALLEGRA Plus THV System in Patients With Severe Aortic Stenosis or Failed Surgical Aortic Bioprosthesis
Acronym
EMPIRE-II
Condition
Transcatheter Aortic Valve Implantation
Intervention (Device)
(ALLEGRA Plus Transcatheter Heart Valve) TAVI in severe calcified aortic stenosis or in failed surgical aortic bioprosthesis
Lead sponsor
NVT GmbH (class: industry)

Record details

Record id
cardio:ct-nct05804903
Content hash
a8b2fa823df4cce659d7a0b7d19633151d76e65311b97879a230ee2ca4547e22